| Price | Rs 350.47 |
| ZEME fair value | Rs 383.59 |
| Discount to fair value | 9.5% |
| Smart-money phase | Fully Loaded |
| Confidence score | 50/100 |
| RSI (14) | 40.8 |
| P/E | 10.6 |
| ROE | —% |
| Dividend yield | 4.8% |
| 52-week range | Rs 293.08 – Rs 451.80 |
| Sector | Pharmaceuticals |
| Shariah-compliant | Yes ☪ |
GLAXO (GlaxoSmithKline Pakistan Limited) trades at Rs 350.47 on the Pakistan Stock Exchange, in the Fully Loaded smart-money phase — accumulated. ZEME's model puts fair value near Rs 383.59, making it about 9.5% undervalued. Smart money has fully loaded the position — a mature bullish setup, often before a markup.
ZEME AI reads GLAXO through operator accumulation/distribution phases, fair value across three methods, RSI and volume, plus institutional flow (FIPI/LIPI & off-market) — the same smart-money engine behind our daily PSX signals. For the live chart, entry/stop/target and history, open the interactive analysis above.
Yes — on ZEME's read, it shows smart-money accumulation AND trades below fair value. Smart money has fully loaded the position — a mature bullish setup, often before a markup. As of 20 Jul 2026, GLAXO is in the Fully Loaded phase with a ZEME confidence score of 50/100.
ZEME estimates GLAXO's fair value at about Rs 383.59, versus a market price of Rs 350.47 — roughly 9.5% undervalued.
GLAXO is currently in the Fully Loaded phase. Smart money has fully loaded the position — a mature bullish setup, often before a markup.
Data updated 20 Jul 2026 from ZEME AI's PSX engine. Educational analytics, not investment advice — do your own research and use a stop loss. Trading carries risk.